Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGER | Q15109 | 3/20 | 1.00 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.76 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.61 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.61 |
| ▸ | SLC6A9 | P48067 | 4/20 | 0.53 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL95632 | 0.86 | AGER (0.76) | AGERMTNR1ACHRM2CHRM3SLC6A9 | |
| SCHEMBL1168805 | 0.83 | AGER (0.71) | AGERMTNR1ACHRM2CHRM3SLC6A9 | |
| SCHEMBL2814615 | 0.81 | AGER (0.67) | AGERMTNR1ACHRM2CHRM3HSD17B10 | |
| SCHEMBL11621108 | 0.80 | AGER (0.66) | AGERMTNR1ASLC6A9SLC6A5MEN1 | |
| SCHEMBL7802288 | 0.79 | DCUN1D1 (0.66) | AGERSLC6A9SLC6A5ALDH1A1 | |
| SCHEMBL11434676 | 0.78 | AGER (0.63) | AGERMTNR1AOPRM1HTTALDH1A1 | |
| SCHEMBL11621624 | 0.78 | AGER (0.64) | AGERSLC6A9SLC6A5HSD17B10LMNA | |
| SCHEMBL11321347 | 0.77 | AGER (0.63) | AGERMTNR1ASLC6A9SLC6A5MEN1 | |
| SCHEMBL23175993 | 0.77 | AGER (0.63) | AGERMTNR1ACHRM2CHRM3MEN1 | |
| Pencycuron SCHEMBL8817027 | 0.76 | AGER (0.62) | AGERSLC6A9SLC6A5HSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4736875-A1 | USE OF RAGE RECEPTOR INHIBITOR IN PREPARATION OF DRUG FOR INHIBITING LYMPHOCYTE REDUCTION OR DEATH | The Third Xiangya Hospital of Central South University (CN) | 2026-05-06 | — | — | EP | claimed |
| EP-4736877-A1 | PHARMACEUTICAL COMPOSITION AND USE THEREOF | The Third Xiangya Hospital of Central South University (CN) | 2026-05-06 | — | — | EP | claimed |
| EP-4676453-A1 | METHODS FOR THE TREATMENT OF FOOD ALLERGY | Institut National de la Santé et de la Recherche Médicale (FR) | 2026-01-14 | — | — | EP | claimed |
| US-20250340837-A1 | CELLS | UNIVERSITY OF GENEVA (CH) | 2025-11-06 | — | — | US | claimed |
| WO-2025217379-A1 | DRUG TREATMENT FOR MACULAR DEGENERATION | UNIVERSITY OF ROCHESTER (US) | 2025-10-16 | — | — | WO | claimed |
| US-20250281638-A1 | Compositions and Methods for Activating Natural Killer Cells | CHIMERA BIOENGINEERING, INC. (US) | 2025-09-11 | — | — | US | claimed |
| WO-2025122021-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF), THROUGH TARGETING OF S100A9 AND CORRESPONDING DIMER PARTNER AND RECEPTORS | I3S - INSTITUTO DE INVESTIGAÇÃO E INOVAÇÃO EM SAÚDE, ASSOCIAÇÃO (PT) | 2025-06-12 | — | — | WO | claimed |
| EP-4504916-A1 | CELLS | University of Geneva (CH) | 2025-02-12 | — | — | EP | claimed |
| CN-118717994-A | Application of S100A8/A9 in induction of NK cells to generate IFNgamma in liver cirrhosis | 浙江大学医学院附属第一医院(浙江省第一医院) | 2024-10-01 | — | — | CN | claimed |
| CN-118703586-A | Use of Rage receptor inhibitors for the preparation of a medicament for inhibiting lymphopenia or death | 中南大学湘雅三医院 | 2024-09-27 | — | — | CN | claimed |
| WO-2024184479-A1 | METHODS FOR THE TREATMENT OF FOOD ALLERGY | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-09-12 | — | — | WO | claimed |
| WO-2024144816-A1 | TREATMENT OF IMMUNOLOGICALLY COLD SOLID TUMORS | CANTEX PHARMACEUTICALS, INC. (US) | 2024-07-04 | — | — | WO | claimed |
| CN-115300526-B | Co-MOF composite nanoparticle loaded with FPS-ZM1 and application thereof | 上海市第六人民医院 | 2024-05-14 | — | — | CN | claimed |
| WO-2023194569-A1 | CELLS | UNIVERSITY OF GENEVA (CH) | 2023-10-12 | — | — | WO | claimed |
| CN-116590765-A | Gloss agent and application thereof | 南通麦特隆新材料科技有限公司 | 2023-08-15 | — | — | CN | claimed |
| WO-2022260968-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING NATURAL KILLER CELLS | CHIMERA BIOENGINEERING, INC. (US) | 2022-12-15 | — | — | WO | claimed |
| CN-115300526-A | FPS-ZM1 loaded Co-MOF composite nanoparticle and application thereof | 上海市第六人民医院 | 2022-11-08 | — | — | CN | claimed |
| WO-2022150709-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-07-14 | — | — | WO | claimed |
| WO-2022125392-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING T-CELLS | CHIMERA BIOENGINEERING, INC. (US) | 2022-06-16 | — | — | WO | claimed |
| US-8778985-B2 | Inhibiting amyloid-beta peptide/rage interaction at the blood-brain barrier | THE UNIVERSITY OF ROCHESTER (US) | 2014-07-15 | — | — | US | claimed |